THE ASSESSMENT OF A WEIGHT-GAIN AGENT FOR THE TREATMENT OF OLANZAPINE-ASSOCIATED ANTI-OBESITY AGENT IN PATIENTS WITH SCHIZOPHRENIA, SCHIZOPHRENIFORM DISORDER, SCHIZOAFFECTIVE DISORDER, AND BIPOLAR I DISORDER: